Literature DB >> 33618750

Are hospitalized patients with inflammatory bowel disease at increased risk of invasive bacterial infections? Results from POLIBD 3-year cohort study.

Jolanta Gruszecka1,2, Rafał Filip3,4.   

Abstract

The aim of this study was to determine the dominant species of bacteria found in blood cultures collected from patients under treatment in the tertiary inflammatory bowel disease (IBD) center in Poland. The dominant pathogen isolated from blood in patients with IBD was Staphylococcus epidermidis MRCNS (MRCNS-methicillin-resistant coagulase-negative Staphylococcus), a strain resistant to all beta-lactam antibiotics (penicillins, penicillins with B-lactamase inhibitor, cephalosporins and carbapenems). The second most commonly isolated pathogen found in the blood samples was Escherichia coli. Blood cultures were found to be positive for these pathogens more frequently in male patients (90.0%). An increased risk of bacteremia in IBD patients was associated with prolonged hospitalization.

Entities:  

Keywords:  Bacteremia; Inflammatory bowel disease; Risk factors

Year:  2021        PMID: 33618750      PMCID: PMC7901178          DOI: 10.1186/s13099-021-00408-6

Source DB:  PubMed          Journal:  Gut Pathog        ISSN: 1757-4749            Impact factor:   4.181


  9 in total

1.  Patterns of Antibiotic Exposure and Clinical Disease Activity in Inflammatory Bowel Disease: A 4-year Prospective Study.

Authors:  Jana G Hashash; Preethi Chintamaneni; Claudia M Ramos Rivers; Ioannis E Koutroubakis; Miguel D Regueiro; Leonard Baidoo; Jason M Swoger; Arthur Barrie; Marc Schwartz; Michael A Dunn; David G Binion
Journal:  Inflamm Bowel Dis       Date:  2015-11       Impact factor: 5.325

2.  Risk of Serious and Opportunistic Infections Associated With Treatment of Inflammatory Bowel Diseases.

Authors:  Julien Kirchgesner; Magali Lemaitre; Fabrice Carrat; Mahmoud Zureik; Franck Carbonnel; Rosemary Dray-Spira
Journal:  Gastroenterology       Date:  2018-04-12       Impact factor: 22.682

3.  Evaluation of the BD BACTEC FX blood volume monitoring system as a continuous quality improvement measure.

Authors:  L Coorevits; A-M Van den Abeele
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2015-04-17       Impact factor: 3.267

4.  The incidence and prognosis of patients with bacteremia.

Authors:  Stig Lønberg Nielsen
Journal:  Dan Med J       Date:  2015-07       Impact factor: 1.240

5.  Comparison of Vitek MS (MALDI-TOF) to standard routine identification methods: an advance but no panacea.

Authors:  Patrick Harris; Ian Winney; Chris Ashhurst-Smith; Mark O'Brien; Stephen Graves
Journal:  Pathology       Date:  2012-10       Impact factor: 5.306

6.  Increased Intestinal Permeability in Relatives of Patients With Crohn's Disease Is Not Associated With Small Bowel Ulcerations.

Authors:  Christopher W Teshima; Karen J Goodman; Mohamed El-Kalla; Samina Turk; Wael El-Matary; Rosica Valcheva; Ronda Danchak; Marilyn Gordon; Peter Ho; Amanda Mullins; Daniel Wong; Dina Kao; Jonathan Meddings; Hien Huynh; Levinus A Dieleman
Journal:  Clin Gastroenterol Hepatol       Date:  2017-03-07       Impact factor: 11.382

7.  Risk of bacteremia in hospitalised patients with inflammatory bowel disease: a 9-year cohort study.

Authors:  Idan Goren; Adi Brom; Henit Yanai; Amir Dagan; Gad Segal; Ariel Israel
Journal:  United European Gastroenterol J       Date:  2019-09-05       Impact factor: 4.623

8.  Serious infection and mortality in patients with Crohn's disease: more than 5 years of follow-up in the TREAT™ registry.

Authors:  Gary R Lichtenstein; Brian G Feagan; Russell D Cohen; Bruce A Salzberg; Robert H Diamond; Samiyeh Price; Wayne Langholff; Anil Londhe; William J Sandborn
Journal:  Am J Gastroenterol       Date:  2012-08-14       Impact factor: 10.864

9.  Impact of appropriate empirical antibiotic treatment on recurrence and mortality in patients with bacteraemia: a population-based cohort study.

Authors:  Kim O Gradel; Ulrich S Jensen; Henrik C Schønheyder; Christian Østergaard; Jenny D Knudsen; Sonja Wehberg; Mette Søgaard
Journal:  BMC Infect Dis       Date:  2017-02-06       Impact factor: 3.090

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.